Xoma Royalty通过战略版税股份交易修改最初于2006年与武田建立的合作

2025-12-30 20:38

Takeda's royalty and milestone payment obligations to XOMA Royalty related to mezagitamab will be reduced
XOMA Royalty will receive payments based on low to mid-single-digit royalties and milestones across a basket of nine development-stage assets that are held within Takeda's externalized assets portfolio.
Takeda regains a majority of XOMA Royalty's royalty interest in mezagitamab (TAK-079)
XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine development-stage assets held within Takeda's externalized assets portfolio